Stockreport

FDA issues complete response to Daiichi Sankyo-MSD's BLA for NSCLC [Yahoo! Finance]

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF approval for patritumab deruxtecan (HER3-DXd) to treat non-small cell lung cancer (NSCLC). The BLA sought accelerated approval for the antibody-drug conjugate for adul [Read more]